Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126127142 | 12612714 | 2 | F | 20160620 | 20160831 | 20160801 | 20160908 | EXP | US-ASTRAZENECA-2016SE69906 | ASTRAZENECA | 21756.00 | DY | F | Y | 73.90000 | KG | 20160908 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126127142 | 12612714 | 1 | PS | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 160/4.5 MCG INHALED TWICE DAILY | U | 21929 | |||||||||
| 126127142 | 12612714 | 2 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 0 | ||||||||||
| 126127142 | 12612714 | 3 | SS | BRILINTA | TICAGRELOR | 1 | Oral | 180.0MG ONCE/SINGLE ADMINISTRATION | U | 22433 | 180 | MG | TABLET | ||||||
| 126127142 | 12612714 | 4 | SS | BRILINTA | TICAGRELOR | 1 | Oral | 180.0MG ONCE/SINGLE ADMINISTRATION | U | 22433 | 180 | MG | TABLET | ||||||
| 126127142 | 12612714 | 5 | SS | BRILINTA | TICAGRELOR | 1 | Oral | 90.0MG ONCE/SINGLE ADMINISTRATION | U | 22433 | 90 | MG | TABLET | BID | |||||
| 126127142 | 12612714 | 6 | SS | BRILINTA | TICAGRELOR | 1 | Oral | 90.0MG ONCE/SINGLE ADMINISTRATION | U | 22433 | 90 | MG | TABLET | BID | |||||
| 126127142 | 12612714 | 7 | SS | LISINOPRIL. | LISINOPRIL | 1 | Oral | U | 0 | 5 | MG | TABLET | QD | ||||||
| 126127142 | 12612714 | 8 | SS | METOPROLOL. | METOPROLOL | 1 | Oral | U | 0 | 25 | MG | TABLET | BID | ||||||
| 126127142 | 12612714 | 9 | C | NITROGLYCERIN. | NITROGLYCERIN | 1 | Sublingual | 0.4 MG AS REQUIRED. | 0 | ||||||||||
| 126127142 | 12612714 | 10 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | 81 | MG | QD | ||||||||
| 126127142 | 12612714 | 11 | C | EFFIENT | PRASUGREL HYDROCHLORIDE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 126127142 | 12612714 | 12 | C | METHOTREXATE. | METHOTREXATE | 1 | Oral | 0 | 7.5 | MG | /wk | ||||||||
| 126127142 | 12612714 | 13 | C | ZANTAC | RANITIDINE HYDROCHLORIDE | 1 | Oral | 0 | 150 | MG | BID | ||||||||
| 126127142 | 12612714 | 14 | C | PROMETHAZINE | PROMETHAZINEPROMETHAZINE HYDROCHLORIDE | 1 | 0 | 25 | MG | Q12H | |||||||||
| 126127142 | 12612714 | 15 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 0 | 300 | MG | TID | ||||||||
| 126127142 | 12612714 | 16 | C | FOLIC ACID. | FOLIC ACID | 1 | Oral | 0 | 1 | MG | QD | ||||||||
| 126127142 | 12612714 | 17 | C | HYDROCODONE | HYDROCODONE | 1 | 7.5/325 TWO TIMES A DAY | 0 | |||||||||||
| 126127142 | 12612714 | 18 | C | NICOTINE. | NICOTINE | 1 | 21.0MG UNKNOWN | 0 | 21 | MG | TRANSDERMAL PATCH | ||||||||
| 126127142 | 12612714 | 19 | C | XANAX | ALPRAZOLAM | 1 | 0.25 MG EVERY SIX HOURS AS NEEDED | 0 | |||||||||||
| 126127142 | 12612714 | 20 | C | ALBUTEROL. | ALBUTEROL | 1 | INHALED FOUR TIMES DAILY | 0 | |||||||||||
| 126127142 | 12612714 | 21 | C | VENTOLIN | ALBUTEROL SULFATE | 1 | 90 MCG ONE-TWO PUFFS INHALED AS NEEDED | 0 | |||||||||||
| 126127142 | 12612714 | 22 | C | TYLENOL | ACETAMINOPHEN | 1 | 650 MG EVERY FOUR HOUR AS NEEDED | 0 | |||||||||||
| 126127142 | 12612714 | 23 | C | HYZAAR | HYDROCHLOROTHIAZIDELOSARTAN POTASSIUM | 1 | 100/25 MG DAILY | 0 | |||||||||||
| 126127142 | 12612714 | 24 | C | NORVASC | AMLODIPINE BESYLATE | 1 | 0 | 5 | MG | QD | |||||||||
| 126127142 | 12612714 | 25 | C | COMBIVENT | ALBUTEROL SULFATEIPRATROPIUM BROMIDE | 1 | INHLAED FOUR TIMES DAILY AS NEEDED | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126127142 | 12612714 | 3 | Stent placement |
| 126127142 | 12612714 | 4 | Percutaneous coronary intervention |
| 126127142 | 12612714 | 5 | Stent placement |
| 126127142 | 12612714 | 6 | Percutaneous coronary intervention |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126127142 | 12612714 | OT |
| 126127142 | 12612714 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126127142 | 12612714 | Acute myocardial infarction | |
| 126127142 | 12612714 | Coronary artery disease | |
| 126127142 | 12612714 | Ejection fraction decreased | |
| 126127142 | 12612714 | Hyperlipidaemia | |
| 126127142 | 12612714 | Hypertension | |
| 126127142 | 12612714 | Hypoaesthesia | |
| 126127142 | 12612714 | Hypokinesia | |
| 126127142 | 12612714 | Ischaemic cardiomyopathy | |
| 126127142 | 12612714 | Myocardial infarction | |
| 126127142 | 12612714 | Thrombosis | |
| 126127142 | 12612714 | Vascular pseudoaneurysm | |
| 126127142 | 12612714 | Ventricular hypokinesia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126127142 | 12612714 | 3 | 20160614 | 20160614 | 0 | |
| 126127142 | 12612714 | 4 | 20160614 | 20160614 | 0 |